Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × mocetinostat × Clear all
NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Mirati Therapeutics Inc.

Phase 2 Terminated
161 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02303262 2019-01-29

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
20 enrolled 11 charts
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡